Background
Methods
Inclusion and exclusion criteria
Search strategy and study selection
Methodological assessment and data extraction
Statistical analyses
Results
Search results
Assessment of methodological quality and heterogeneity between two groups
Summary of outcomes of each article
Authors | Level of Evidence | Design | Cases | Mean age (y, range) | Mean FU (m, range) | Range of motion | Outcome measurements |
---|---|---|---|---|---|---|---|
Cemented all-polyethylene glenoid components (PEG) | |||||||
Raiss (2008) | IV | Aequalisa | 21 | 55 (37–60) | 7 years (5–9) | FE, ABD, IR, ER | Constant score |
Rice (2008) | IV | Cofield IIb | 14 | 66 (52–78) | 5 years (2–8) | ABD, ER | Neer result rating |
Fox (2009) | IV | Mixedc | 972 | 66.4 | 68.1 | N | N |
Edwards (2010) | I | Aequalisa | 47 | 69 ± 11 | 26 (12–38) | N | N |
Throckmorton (2010) | III | Cofield | 100 | 68.6 (52–80) | 48.5 (24–98) | FE, IR, ER | VAS |
Arnold (2011) | IV | Global Advantaged | 35 | 70 (49–89) | 43 (24–66) | N | Constant score |
Collin (2011) | II | Aequalisa | 56 | 66.7 (43–83) | 120 (102–155) | N | N |
Walch (2011) | IV | Aequalisa | 333 | 69.3 (35–90) | 89.5 (61–152) | FE, ER | Constant score |
Young (2011) | IV | Aequalisa | 226 | 66.9 (40–90) | 122.7 (61–219) | FE, ER | Constant score |
Raiss (2012) | IV | Aequalisa | 39 | 64 (43–79) | 132 (120–180) | FE, ABD, IR, ER | Constant score |
Wirth (2012) | IV | Global Advantaged | 44 | 66 (52–79) | 48 (24–84) | FE, IR, ER | VAS, ASES score, SST |
Denard (2013) | IV | Aequalisa | 50 | 50.5 (35–55) | 115.5 (60–211) | FE, ER | Constant score |
Greiner (2013) | IV | Affinise | 97 | 66.6 (30–85) | 58.8 (31.2–92.5) | FE, ABD | Constant score |
Raiss (2014) | IV | N (mixed) | 329 | N | 8.0 years (4–17) | FE, ER | Constant score |
Gazielly (2015) | IV | Aequalisa | 39 | 68.1 (51–81) | 102 (56.4–150) | FE, ER | Constant score, pain score |
Gulotta (2015) | III | BioModularf | 40 | 68.2 ± 9.1 | 38 (24–45) | N | VAS, ASES |
Noyes (2015) | IV | Global Advantaged | 42 | 64 (51–80) | 80 (63–114) | FE, ER | ASES |
Wright (2015) | IV | Equinoxeg | 24 | 66.4 ± 9.1 | 29.6 ± 8.7 | FE, ABD, IR, ER | Constant score, ASES, SST, UCLA |
Parks (2016) | IV | Affinitih | 76 | 63.5 (39–86) | 28.7 (24–60) | FE, ABD, IR, ER | Constant score, ASES |
Wijeratna (2016) | IV | Global Advantaged | 83 | 68.6 (49–88) | 46.7 (24–99) | FE, IR, ER | ASES, Oxford score |
McLendon (2017) | IV | Cofield IIi | 287 | 65 (21–85) | 84 (48–171.6) | N | N |
Service (2017) | III | Global Advantaged | 71 | 68 ± 8.3 | 30 ± 7.2 | N | SST |
Gauci (2018) | III | Aequalisa | 46 | 55(40–60) | 123.6 ± 26 (60–144) | FE, ER | VAS, Constant score, SSV |
Raiss (2018) | IV | Aequalisj | 118 | 68 (51–85) | 38 (24–70) | N | N |
Sanchez-Sotelo (2018) | 2018/IV | PEG | 202 | 67 (24–93) | 32.4 (24–60) | FE, IR, ER | ASES |
Modern design of metal-backed glenoid component (MBG) | |||||||
Castagna (2010) | IV | Second-generation SMRl | 35 | 62.7 (55.3–70.1) | 75.4 | N | VAS, Constant score, SST |
Fucentese (2010) | IV | Sulmeshm | 22 | 68.5 (49–84) | 50 (24–89) | N | Constant score |
Budge (2013) | IV | Tantalum TMn | 19 | 62.8 ± 14.6 | 31 (24–64) | ER | VAS, ASES score |
Styron (2016) | IV | Tantalum TMn | 66 | 66.2 (31–88) | 50.2 | FE, IR, ER | N |
Sandow (2016) | IV | Tantalum TMn | 10 | (60–79) | 24 | FE | VAS, Oxford score, ASES score |
Panti (2016) | IV | Tantalum TMn | 76 | 69.6 (52–81) | 43.2 (24–72) | FE, ABD, ER | VAS, ASES score |
Endrizzi (2016) | IV | Tantalum TMn | 73 | 67.5 ± 8.6 (46–85) | 50.8 (24–68) | N | VAS, ASES score |
Merolla (2016) | IV | Tantalum TMn | 40 | 63.8 (40–75) | 38 (24–42) | FE, ABD, ER | Health state, Constant score, ASES score |
Gurin (2017) | IV | Tantalum TMn | 80 | N | 100 | N | VAS |
Watson (2018) | IV | Tantalum TMn | 36 | 66.36 (50–85) | 34.1 (23–61) | FE, ER | VAS, SANE score, Penn score, ASES score |
Common outcome measurements | Radiolucency, loosening, complication, and revision surgery (failure) |
Authors | Cases | Gain of FE (°) | Gain of ER (°) | Radiolucency | Loosening | Revision surgeries | Other reoperations |
---|---|---|---|---|---|---|---|
Cemented all-polyethylene glenoid components (PEG) | |||||||
Raiss (2008) | 21 | 50.7 | 28.1 | 10 (48%) | 10 | 0 | 0 |
Rice (2008) | 14 | N | 21 | 1 (7%) | 1 | 0 | 0 |
Fox (2009) | 972 | N | N | N | 15 | 26 | 0 |
Edwards (2010) | 47 | N | N | N | 0 | 2 | 0 |
Throckmorton (2010) | 100 | 48.3 | 28.6 | N | 10 | 0 | 0 |
Arnold (2011) | 35 | N | N | 5 | 0 | 0 | 0 |
Collin (2011) | 56 | N | N | N | 20 | 3 | 2: RC repair |
Walch (2011) | 333 | 51.7 | 26.3 | 96 | 57 | 5 | 3: open contracture release |
Young (2011) | 226 | 39.7 | 23.3 | 144 | 99 | 37 | 2: Periprosthetic fracture 3: instability 2: RC repair 2: infection 2: stiffness |
Raiss (2012) | 39 | 49 | 24 | N | N | 1 | 0 |
Wirth (2012) | 44 | 141.9 | 34.6 | N | N | 1 | 0 |
Denard (2013) | 50 | 31 | 21 | 30 of 48 | 21 of 48 | 17 | 0 |
Greiner (2013) | 97 | 59.6 | N | 9 | 3 | 7 | 0 |
Raiss (2014) | 250 | 46.9 | 25.0 | N | 100 | 22 | 0 |
Gazielly (2015) | 39 | 42.4 | 25.7 | 8 | 6 | 1 | 0 |
Gulotta (2015) | 40 | N | N | N | 0 | 0 | 1 infection 1 biceps tendinitis |
Noyes (2015) | 42 | 30 | 7 | 8 | N | 1 | 0 |
Wright (2015) | 24 | 44.2 | 24.8 | 5 of 15 | 0 | 0 | 0 |
Parks (2016) | 76 | 31 | 13 | 14 | 1 | 7 of 80 | N |
Wijeratna (2016) | 83 | N | N | 5 | 1 | 1 | 3 contracture release 1: RC repair 1: capsular plication |
McLendon (2017) | 287 | N | N | N | 120 | 36 | 0 |
Service (2017) | 71 | N | N | 19 | 1 | 3 | 0 |
Gauci (2018) | 46 | 40 | 26 | N | 10 | 10 | N |
Raiss (2018) | 118 | N | N | N | 0 | 2 | 0 |
Sanchez-Sotelo (2018) | 202 | N | N | 0 | 0 | 7 | 2 |
Modern design of metal-backed glenoid component (MBG) | |||||||
Castagna (2010) | 35 | N | N | 8 (22%) | 0 | 0 | 0 |
Fucentese (2010) | 22 | N | N | N | 3 (14%) | 3 (14%) | 0 |
Budge (2013) | 19 | N | 44 | 7 (37%) | 4 (21%) | 3 (16%) | N |
Styron (2016) | 66 | 70 | 36 | N | 13 of 58 (23%) | 1 (2%) | N |
Sandow (2016) | 10 | N | N | 0 | 0 | 0 | 0 |
Panti (2016) | 76 | 54.4 | 40.8 | 5 (7%) | 0 | 0 | 1: RC repair |
Endrizzi (2016) | 73 | N | N | 24 of 66 (36.4%) | 1 of 66 (1.5%) | 1 (1%) | 0 |
Merolla (2016) | 40 | N | N | 2 (5%) | 0 | 0 | 0 |
Gurin (2017) | 80 | N | N | N | 0 | 2 (3%) | 0 |
Watson (2018) | 36 | N | N | 1 (2.8%) | 1 (2.8%) | 1 (3%) | N |
Clinical outcomes and complications of cemented PEG and modern MBG groups
Cemented PEG (n = 3312) | Modern MBG (n = 457) | P–value | ||
---|---|---|---|---|
Age (years) | Number of cases/articles | 3062/24 | 367/8 | NA |
Mean | 66.4 (21–93) | 66.5 (31–88) | ||
Follow–up duration (months) | Number of cases/articles | 3312/25 | 457/10 | NA |
Mean | 73.1 (12–211) | 56.1 | ||
Gain of FE (°) | Number of cases/articles | 1387/14 | 142/2 | NA |
Mean | 48.6 | 61.7 | ||
Gain of ER (°) | Number of cases/articles | 1304/14 | 161/3 | NA |
Mean | 24.2 | 39.2 | ||
Constant score improvement | Number of cases/articles | 1208/9 | 3/97 | NA |
Mean | 34.8 | 40.4 | ||
ASES score improvement | Number of cases/articles | 226/5 | 135/3 | NA |
Mean | 44.5 | 56.5 | ||
Primary osteoarthritis | Yes (%) | 2866 (86.5%) | 350 (88.4%) | 0.310 |
No (%) | 446 (13.5%) | 46 (11.6%) | ||
Diagnosis unknown | 1 | 61 | ||
Radiolucent lines | Present (%) | 354 (27.2%) | 22 (4.9%) | NA |
Absent (%) | 948 (72.8%) | 427 (95.1%) | ||
Not reported | 2010 | 8 | ||
Loosening | Present (%) | 465 (14.6%) | 22 (4.9%) | NA |
Absent (%) | 2720 (85.4%) | 427 (95.1%) | ||
Not reported | 127 | 8 | ||
Revision surgery | Present (%) | 189 (5.7%) | 11 (2.4%) | NA |
Absent (%) | 3127 (94.3%) | 446 (97.6%) | ||
Not reported | 0 | 0 |
Scatter plots and subgroup analysis according to the FU duration
Items | <36-month subgroupa | 36–72-month subgroupb | >72-month subgroupc | |||
---|---|---|---|---|---|---|
PEG | MBG | PEG | MBG | PEG | MBG | |
Age (years) | 66.7 | 64.8 | 66.9 | 67.3 | 65.3 | 62.7 |
Number of radiolucency (%) | 38/439 (7.3%) | 8/65 (12.3%) | 20/229 (8.7%) | 31/182 (17.0%) | 296/709 (41.7%) | 8/35 (22.9%) |
P = 0.355 | P = 0.015 * | P = 0.033 * | ||||
Number of loosening | 2/420 (0.5%) | 5/65 (7.7%) | 19/1459 (1.3%) | 17/269 (6.3%) | 443/1306 (33.9%) | 0/115 (0%) |
P < 0.001 * | P < 0.001 * | P < 0.001 * | ||||
Number of failure (=revision) | 19/424 (4.5%) | 4/65 (6.2%) | 37/1503 (2.5%) | 5/277 (1.8%) | 133/1389 (9.6%) | 2/115 (1.7%) |
P = 0.754 | P = 0.829 | P = 0.002 * |
Items | <36-month subgroupa | 36–72-month subgroupb | > 72-month subgroupc | |||
---|---|---|---|---|---|---|
PEG | MBG | PEG | MBG | PEG | MBG | |
Age (years) | 66.7 | 64.8 | 66.9 | 67.3 | 66.7 | 62.7 |
Number of radiolucency (%) | 38/439 (7.3%) | 8/65 (12.3%) | 20/229 (8.7%) | 31/182 (17.0%) | 256/640 (40.0%) | 8/35 (22.9%) |
P = 0.355 | P = 0.015 * | P = 0.05 | ||||
Number of loosening | 2/420 (0.5%) | 5/65 (7.7%) | 19/1459 (1.3%) | 17/269 (6.3%) | 402/1191 (33.8%) | 0/115 (0%) |
P < 0.001 * | P < 0.001 * | P < 0.001 * | ||||
Number of failure (=revision) | 19/424 (4.5%) | 4/65 (6.2%) | 37/1503 (2.5%) | 5/277 (1.8%) | 106/1272 (8.3%) | 2/115 (1.7%) |
P = 0.754 | P = 0.829 | P = 0.006 * |